- Home
- BL vs NVCR Comparison
BL vs NVCR Comparison
Compare BL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BL | NVCR |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BL | NVCR |
|---|---|---|
| Price | $29.95 | $16.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $56.62 | $28.08 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.13 | N/A |
| Revenue | $177,031,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $12.62 | $7.72 |
| Revenue Next Year | $10.90 | $6.74 |
| P/E Ratio | $229.85 | ★ N/A |
| Revenue Growth | ★ 43.78 | 8.28 |
| 52 Week Low | $24.70 | $9.82 |
| 52 Week High | $59.57 | $18.92 |
Technical Indicators
Market Signals| Indicator | BL | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 56.90 |
| Support Level | $29.23 | $12.79 |
| Resistance Level | $31.23 | $18.59 |
| Average True Range (ATR) | 1.33 | 0.83 |
| MACD | 0.37 | 0.02 |
| Stochastic Oscillator | 95.93 | 76.47 |
Price Performance
Historical ComparisonAbout BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.